Investigational drug · Phase 2
MEDI0618
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Migraine.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "MEDI0618"
First trial start
2024
Oct 7, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MEDI0618", any sponsor or status.
Conditions studied
As listed on its trial records.
- Migraine
Approved drugs for the same conditions: Migraine · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "MEDI0618" as an intervention, largest first.
- A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic MigrainePivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06602479 · 309 participants · Start Oct 7, 2024 · Primary completion Feb 2027
Drug: MEDI0618; Placebo · For: Migraine
Sites: Birmingham, Alabama; Huntsville, Alabama; Gilbert, Arizona · 71 sites in all
AstraZenecaAstraZeneca (AZN)
NCT04198558 · 64 participants · Start Nov 29, 2019 · Primary completion Feb 23, 2022
Drug: MEDI0618; Placebo · For: Chronic Pain
Sites: Berlin, Germany
AstraZenecaAstraZeneca (AZN)
NCT05714254 · 36 participants · Start Dec 12, 2022 · Primary completion Dec 12, 2023
Drug: MEDI0618; Placebo · For: Chronic Pain
Sites: Berlin, Germany
Newest research
PubMed records naming it or its code names, newest first.
- Efficacy of MEDI0618, a pH-dependent monoclonal antibody targeting PAR2, in preclinical models of migraine.
Kopruszinski CM, Linley JE, Thornton P, et al. · Brain 2025
- The development of proteinase-activated receptor-2 modulators and the challenges involved.
McIntosh KA, Cunningham MR, Bushell T, et al. · Biochem Soc Trans 2020
Also in development for Migraine
- AXS-07meloxicam-rizatriptanPhase 31 trial
Axsome Therapeutics, Inc. · Migraine
- EVO756Phase 24 trials
Evommune, Inc. · Migraine, Chronic Inducible Urticaria, Atopic Dermatitis
- BHV-2100Phase 21 trial
Biohaven Therapeutics Ltd. · Migraine
- MTX101Phase 21 trial
Manistee Therapeutics · Migraine
- PRT-064040Phase 21 trial
Sichuan Purity Pharmaceutical Technology Co., Ltd. · Migraine
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.